Cowen and Company restated their outperform rating on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research report released on Friday. Cowen and Company currently has a $55.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $45.00.
Several other research analysts have also commented on the company. BidaskClub raised Adamas Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday. Zacks Investment Research lowered Adamas Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 11th. Noble Financial reaffirmed a buy rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Mizuho reaffirmed a buy rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $32.50.
Adamas Pharmaceuticals (ADMS) traded up 40.06% during trading on Friday, hitting $19.93. 13,964,372 shares of the company were exchanged. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $21.44. The stock’s market capitalization is $448.70 million. The firm’s 50 day moving average price is $16.54 and its 200-day moving average price is $16.78.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.81) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The company’s quarterly revenue was down 90.9% on a year-over-year basis. During the same period last year, the firm earned ($0.78) EPS. Equities analysts predict that Adamas Pharmaceuticals will post ($3.80) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Given Outperform Rating at Cowen and Company” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/26/adamas-pharmaceuticals-inc-adms-given-outperform-rating-at-cowen-and-company.html.
In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $17.05, for a total value of $5,967,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 731,041 shares of company stock worth $12,476,149 over the last quarter. Company insiders own 29.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in ADMS. State Street Corp increased its position in shares of Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock valued at $2,138,000 after buying an additional 28,994 shares during the period. Wells Fargo & Company MN increased its position in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the period. Bank of New York Mellon Corp increased its position in shares of Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock valued at $1,152,000 after buying an additional 1,563 shares during the period. Finally, Parametric Portfolio Associates LLC increased its position in shares of Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares during the period. Institutional investors own 70.86% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
